Humacyte, Inc. (HUMA)
0.465
-0.01
(-2.72%)
USD |
NASDAQ |
Oct 07, 12:37
Humacyte Enterprise Value : 118.92M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 118.92M |
| October 05, 2026 | 125.03M |
| October 02, 2026 | 131.00M |
| October 01, 2026 | 125.84M |
| September 30, 2026 | 129.95M |
| September 29, 2026 | 134.12M |
| September 28, 2026 | 138.14M |
| September 25, 2026 | 140.95M |
| September 24, 2026 | 144.12M |
| September 23, 2026 | 143.28M |
| September 22, 2026 | 148.03M |
| September 21, 2026 | 150.03M |
| September 18, 2026 | 148.81M |
| September 17, 2026 | 145.89M |
| September 16, 2026 | 144.48M |
| September 15, 2026 | 139.37M |
| September 14, 2026 | 141.98M |
| September 11, 2026 | 143.81M |
| September 10, 2026 | 143.67M |
| September 09, 2026 | 146.98M |
| September 08, 2026 | 151.40M |
| September 04, 2026 | 154.17M |
| September 03, 2026 | 151.70M |
| September 02, 2026 | 151.87M |
| September 01, 2026 | 144.59M |
| Date | Value |
|---|---|
| August 31, 2026 | 153.20M |
| August 28, 2026 | 166.73M |
| August 27, 2026 | 178.56M |
| August 26, 2026 | 175.48M |
| August 25, 2026 | 180.92M |
| August 24, 2026 | 170.09M |
| August 21, 2026 | 164.53M |
| August 20, 2026 | 175.42M |
| August 19, 2026 | 190.29M |
| August 18, 2026 | 147.73M |
| August 17, 2026 | 141.87M |
| August 14, 2026 | 154.15M |
| August 13, 2026 | 138.92M |
| August 12, 2026 | 170.87M |
| August 11, 2026 | 183.37M |
| August 10, 2026 | 192.95M |
| August 07, 2026 | 185.65M |
| August 06, 2026 | 183.26M |
| August 05, 2026 | 188.59M |
| August 04, 2026 | 183.98M |
| August 03, 2026 | 177.62M |
| July 31, 2026 | 167.65M |
| July 30, 2026 | 172.70M |
| July 29, 2026 | 159.65M |
| July 28, 2026 | 161.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 260.96B |
| Altimmune, Inc. | 228.94M |
| Protalix Biotherapeutics, Inc. | 187.79M |
| Taysha Gene Therapies, Inc. | 1.030B |
| Agenus, Inc. | 583.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.80M |
| Revenue (Quarterly) | 0.406M |
| Total Expenses (Quarterly) | 37.21M |
| EPS Diluted (Quarterly) | -0.1572 |
| Gross Profit Margin (Quarterly) | -423.2% |
| Profit Margin (Quarterly) | -9.06K% |
| Earnings Yield | -105.3% |
| Normalized Earnings Yield | -125.72 |